Novasep announces Nadege Laborde as new president of its industrial biotech business unit

6 December 2013
laborde-big

The France-based biotechnology company Novasep has announced Nadege Laborde as the new president of its industrial biotech business unit. It hopes this internal promotion will strengthen the business unit and enhance the Executive Committee.

Ms Laborde will be the new president of Novasep’s Industrial Biotech business unit, the company announced from its headquarters in Pompey, France. Novasep, a leading supplier of manufacturing solutions to the life sciences industry, states that Ms Laborde will pose a key addition to the Executive Committee and expand the company’s market reach into new geographical territories.

The nomination recognizes and rewards the commitment and skill that Ms Laborde has demonstrated within the business since joining Novasep in 2000. Beginning her career as a project manager, Ms Laborde then expanded her responsibilities to become an engineering manager in the USA and Asia. Since 2009 she has headed the system engineering and construction department, enabling an average double-digit growth of industrial biotech unit sales over the last four years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology